Singapore's Experimental Drug Development Centre inks new collaboration with Chinese startup XtalPi

Empowering biomedical innovation with robotics and large language models

XtalPi, an innovative technology company powered by artificial intelligence (AI) and robotics, has signed a Memorandum of Understanding (MoU) with the Experimental Drug Development Centre (EDDC), Singapore's national drug discovery and development platform hosted by A*STAR, for the expansion of their collaboration to encompass potential projects that will focus on the application of automated synthesis solutions and large language models in pharmaceutical research.

Building upon an ongoing collaboration that was initiated in December 2022 to utilise AI and automation to develop targeted therapies for non-small cell lung cancer, the new collaboration aims to expedite the conversion of scientific discoveries into robust pipeline assets by advancing the domain of intelligent automated pharmaceutical research.

Under the MoU, the two parties will explore collaborations in the fields of automated chemical compound synthesis and AI-driven drug discovery, including the application of XtalPi's robotics and AI-driven drug design capabilities in EDDC's R&D, such as automated library synthesis and other drug chemical synthesis services.

XtalPi's array of automated workstations can provide significant remote support to EDDC's R&D efforts, generating large-scale, high-quality data that can enhance EDDC's current drug development processes. By developing cutting-edge computational tools and industry practices, the partners aim to leverage robotics and AI in therapeutic discovery.

Published on : 23rd November, 2023